MX2021000688A - Anticuerpos anti-cd40 y usos de los mismos. - Google Patents
Anticuerpos anti-cd40 y usos de los mismos.Info
- Publication number
- MX2021000688A MX2021000688A MX2021000688A MX2021000688A MX2021000688A MX 2021000688 A MX2021000688 A MX 2021000688A MX 2021000688 A MX2021000688 A MX 2021000688A MX 2021000688 A MX2021000688 A MX 2021000688A MX 2021000688 A MX2021000688 A MX 2021000688A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- antigen
- disclosure relates
- binding fragments
- tnf receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/096494 WO2020014974A1 (en) | 2018-07-20 | 2018-07-20 | Anti-cd40 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000688A true MX2021000688A (es) | 2021-03-25 |
Family
ID=69164892
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000688A MX2021000688A (es) | 2018-07-20 | 2018-07-20 | Anticuerpos anti-cd40 y usos de los mismos. |
| MX2025000992A MX2025000992A (es) | 2018-07-20 | 2021-01-18 | Anticuerpos anti-cd40 y usos de los mismos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025000992A MX2025000992A (es) | 2018-07-20 | 2021-01-18 | Anticuerpos anti-cd40 y usos de los mismos |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11142582B2 (https=) |
| EP (1) | EP3823987A4 (https=) |
| JP (2) | JP7212138B2 (https=) |
| KR (1) | KR102728939B1 (https=) |
| CN (1) | CN112566933B (https=) |
| AU (1) | AU2018432434B2 (https=) |
| BR (1) | BR112021001083A2 (https=) |
| CA (1) | CA3105875A1 (https=) |
| IL (1) | IL280281B2 (https=) |
| MX (2) | MX2021000688A (https=) |
| SG (1) | SG11202100510PA (https=) |
| WO (1) | WO2020014974A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7212138B2 (ja) * | 2018-07-20 | 2023-01-24 | ヨウキュア（ベイジン）バイオファーマ カンパニー リミテッド | 抗ｃｄ４０抗体及びその使用 |
| EP4229096A4 (en) * | 2020-10-14 | 2024-06-12 | Eucure (Beijing) Biopharma Co., Ltd | ANTI-PD-1/CD40 BISPECIFIC ANTIBODIES AND USES THEREOF |
| KR20250005109A (ko) * | 2022-04-15 | 2025-01-09 | 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 | 항-cd40 항체 및 이의 용도 |
| US20230404642A1 (en) * | 2022-06-01 | 2023-12-21 | Syncromune, Inc. | Method for the treatment of cancer via tumor cell lysis and intratumoral administration of combinations of immunotherapeutic ingredients |
| CN116023495B (zh) * | 2022-09-05 | 2023-10-03 | 上海百英生物科技股份有限公司 | 一种抗cd40纳米抗体及其制备方法与应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| JP4041535B2 (ja) | 1989-08-18 | 2008-01-30 | オックスフォード バイオメディカ（ユーケー）リミテッド | 標的細胞にベクター構造体を運搬する組換レトロウィルス |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| WO2007130493A2 (en) | 2006-05-03 | 2007-11-15 | Regents Of The University Of Colorado | Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| DK2406286T3 (en) * | 2009-03-10 | 2016-08-22 | Baylor Res Inst | Anti-cd40 antibodies and uses thereof |
| SI2531527T1 (sl) | 2010-02-04 | 2014-07-31 | F. Hoffmann-La Roche Ag | Monoklonsko protitelo proti CD44 za uporabo pri zdravljenju skvamoznoceličnega karcinoma glave in vratu |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| CN113461819B (zh) | 2011-04-29 | 2024-01-02 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
| AU2013337903B2 (en) | 2012-10-30 | 2018-08-16 | Apexigen, Inc. | Anti-CD40 antibodies and methods of use |
| HK1252666A1 (zh) * | 2015-06-29 | 2019-05-31 | Bristol-Myers Squibb Company | 针对cd40的抗体 |
| WO2017040932A1 (en) * | 2015-09-04 | 2017-03-09 | Primatope Therapeutics Inc. | Humanized anti-cd40 antibodies and uses thereof |
| US12297266B2 (en) | 2016-04-18 | 2025-05-13 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human CD40 and uses thereof |
| WO2018233607A1 (en) | 2017-06-19 | 2018-12-27 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric cd40 |
| JP7212138B2 (ja) * | 2018-07-20 | 2023-01-24 | ヨウキュア（ベイジン）バイオファーマ カンパニー リミテッド | 抗ｃｄ４０抗体及びその使用 |
-
2018
- 2018-07-20 JP JP2021504146A patent/JP7212138B2/ja active Active
- 2018-07-20 EP EP18927035.8A patent/EP3823987A4/en active Pending
- 2018-07-20 CN CN201880095772.4A patent/CN112566933B/zh active Active
- 2018-07-20 WO PCT/CN2018/096494 patent/WO2020014974A1/en not_active Ceased
- 2018-07-20 AU AU2018432434A patent/AU2018432434B2/en active Active
- 2018-07-20 CA CA3105875A patent/CA3105875A1/en active Pending
- 2018-07-20 BR BR112021001083-1A patent/BR112021001083A2/pt unknown
- 2018-07-20 MX MX2021000688A patent/MX2021000688A/es unknown
- 2018-07-20 KR KR1020217004891A patent/KR102728939B1/ko active Active
- 2018-07-20 IL IL280281A patent/IL280281B2/en unknown
- 2018-07-20 SG SG11202100510PA patent/SG11202100510PA/en unknown
-
2021
- 2021-01-14 US US17/149,209 patent/US11142582B2/en active Active
- 2021-01-18 MX MX2025000992A patent/MX2025000992A/es unknown
- 2021-09-08 US US17/469,488 patent/US12134653B2/en active Active
-
2023
- 2023-01-12 JP JP2023003355A patent/JP2023037000A/ja active Pending
-
2024
- 2024-09-30 US US18/901,856 patent/US20250034271A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2025000992A (es) | 2025-03-07 |
| IL280281B2 (en) | 2025-08-01 |
| CN112566933B (zh) | 2023-07-14 |
| IL280281A (en) | 2021-03-25 |
| AU2018432434A1 (en) | 2021-01-28 |
| US12134653B2 (en) | 2024-11-05 |
| JP2022500004A (ja) | 2022-01-04 |
| US20250034271A1 (en) | 2025-01-30 |
| US20210403588A1 (en) | 2021-12-30 |
| US11142582B2 (en) | 2021-10-12 |
| BR112021001083A2 (pt) | 2021-05-11 |
| WO2020014974A1 (en) | 2020-01-23 |
| EP3823987A1 (en) | 2021-05-26 |
| US20210155705A1 (en) | 2021-05-27 |
| JP7212138B2 (ja) | 2023-01-24 |
| IL280281B1 (en) | 2025-04-01 |
| EP3823987A4 (en) | 2022-03-02 |
| AU2018432434B2 (en) | 2025-11-20 |
| CA3105875A1 (en) | 2020-01-23 |
| SG11202100510PA (en) | 2021-02-25 |
| KR102728939B1 (ko) | 2024-11-11 |
| JP2023037000A (ja) | 2023-03-14 |
| KR20210033029A (ko) | 2021-03-25 |
| CN112566933A (zh) | 2021-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021000688A (es) | Anticuerpos anti-cd40 y usos de los mismos. | |
| ZA202211577B (en) | Multivalent and multispecific 41bb-binding fusion proteins | |
| MX2024004017A (es) | Proteinas de fusion de union a ox40 multivalentes y multiespecificas. | |
| BR112022010206A2 (pt) | Receptores de antígeno quiméricos e usos dos mesmos | |
| CR20200539A (es) | Receptores quiméricos de dll3 y métodos para su uso | |
| CO2018005871A2 (es) | Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos | |
| CL2018000461A1 (es) | Anticuerpos biespecíficos con tetravalencia para un receptor de fnt coestimulador. | |
| PH12018500636A1 (en) | Bispecific antibodies specific for a costimulatory tnf receptor | |
| CL2023003607A1 (es) | Anticuerpos anti-ccr8 y usos de los mismos | |
| UY36692A (es) | Anticuerpos anti-cd40 y usos de los mismos | |
| EA202091228A1 (ru) | Антитела, специфичные к иммуноглобулин-подобному транскрипту 3 (ilt3), и их применение | |
| CL2017000885A1 (es) | Anticuerpos anti-ox40 humanizados y usos de los mismos | |
| AR105767A1 (es) | Proteínas de fusión de unión a gitr multivalentes y multiespecíficas | |
| EP3880711A4 (en) | Agonistic tumor necrosis factor receptor superfamily polypeptides | |
| UY36942A (es) | Proteínas de unión a antígeno que activan el receptor de leptina | |
| EP3840782A4 (en) | ANTAGONIST POLYPEPTIDES OF THE ANTI-TUMORS NECROSIS FACTOR RECEPTOR SUPERFAMILY | |
| DK3773910T3 (da) | Humaniseret anti-prostata-specifikt membranantigen(PSMA)-antistof-lægemiddelkonjugater | |
| MX2019011404A (es) | Receptor de antigeno quimerico. | |
| NZ763061A (en) | Anti-ox40 antibodies and uses thereof | |
| EA201890081A1 (ru) | Механизм действия | |
| EP3755722A4 (en) | CD83 BINDING CHIMERA ANTIGEN RECEPTORS | |
| PE20210315A1 (es) | Receptores quimericos de steap1 y metodos de uso de los mismos | |
| EP3788566A4 (en) | PROVISION OF A SERVICES KIOSK | |
| EP3855243A4 (en) | LIGHT ADJUSTMENT DEVICE | |
| AR106785A1 (es) | ANTICUERPO INTEGRINA ANTI-a-V PARA EL TRATAMIENTO DE LA FIBROSIS Y/O LOS TRASTORNOS FIBRÓTICOS |